{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:42:01Z","timestamp":1794634921419,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002655","name":"Terry Fox Foundation","doi-asserted-by":"publisher","award":["122868"],"award-info":[{"award-number":["122868"]}],"id":[{"id":"10.13039\/501100002655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","award":["140935"],"award-info":[{"award-number":["140935"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","award":["121796"],"award-info":[{"award-number":["121796"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13058-016-0744-y","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T08:38:36Z","timestamp":1470645516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9091-2235","authenticated-orcid":false,"given":"Marie-Claude","family":"Bourgeois-Daigneault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Elizabeth","family":"St-Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic Guy","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Pelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia Sadie","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozanne","family":"Arulanandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Falls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Simon","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Cameron","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"key":"744_CR1","doi-asserted-by":"crossref","unstructured":"Weigelt B, Peterse JL, van \u2019t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591\u2013602.","DOI":"10.1038\/nrc1670"},{"key":"744_CR2","unstructured":"Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston Park). 2008;22:1233\u20139."},{"key":"744_CR3","doi-asserted-by":"crossref","unstructured":"Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S, et al. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer. 2012;12:120.","DOI":"10.1186\/1471-2407-12-120"},{"key":"744_CR4","doi-asserted-by":"crossref","unstructured":"Arnal I, Wade RH. How does taxol stabilize microtubules? Curr Biol. 1995;5:900\u20138.","DOI":"10.1016\/S0960-9822(95)00180-1"},{"key":"744_CR5","doi-asserted-by":"crossref","unstructured":"Mahamodhossen YA, Liu W, Rong-Rong Z. Triple-negative breast cancer: new perspectives for novel therapies. Med Oncol. 2013;30:653.","DOI":"10.1007\/s12032-013-0653-1"},{"key":"744_CR6","doi-asserted-by":"crossref","unstructured":"Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M, et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res. 2012;18:771\u201381.","DOI":"10.1007\/s12253-012-9548-2"},{"key":"744_CR7","doi-asserted-by":"crossref","unstructured":"Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821\u20135.","DOI":"10.1038\/77558"},{"key":"744_CR8","doi-asserted-by":"crossref","unstructured":"Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther. 2010;18:1440\u20139.","DOI":"10.1038\/mt.2010.103"},{"key":"744_CR9","doi-asserted-by":"crossref","unstructured":"Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4:263\u201375.","DOI":"10.1016\/S1535-6108(03)00241-1"},{"key":"744_CR10","doi-asserted-by":"crossref","unstructured":"Diallo J-S, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther. 2010;18:1123\u20139.","DOI":"10.1038\/mt.2010.67"},{"key":"744_CR11","doi-asserted-by":"crossref","unstructured":"Arulanandam R, Batenchuk C, Varette O, Zakaria C, Garcia V, Forbes NE, et al. Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat Commun. 015;6:6410.","DOI":"10.1038\/ncomms7410"},{"key":"744_CR12","doi-asserted-by":"crossref","unstructured":"Margolis RL, Wilson L. Addition of colchicine--tubulin complex to microtubule ends: the mechanism of substoichiometric colchicine poisoning. Proc Natl Acad Sci USA. 1977;74:3466\u201370.","DOI":"10.1073\/pnas.74.8.3466"},{"key":"744_CR13","doi-asserted-by":"crossref","unstructured":"Huang B, Sikorski R, Kirn DH, Thorne SH. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther. 2011;18:164\u201372.","DOI":"10.1038\/gt.2010.121"},{"key":"744_CR14","doi-asserted-by":"crossref","unstructured":"Lin S-F, Gao SP, Price DL, Li S, Chou T-C, Singh P, et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res. 2008;14:1519\u201328.","DOI":"10.1158\/1078-0432.CCR-07-4628"},{"key":"744_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jconrel.2015.10.030","volume":"220","author":"DG Roy","year":"2015","unstructured":"Roy DG, Power AT, Bourgeois-Daigneault MC, Falls T, Ferreira L, Stern A, et al. Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy. J Control Release. 2015;220:210\u201321.","journal-title":"J Control Release."},{"key":"744_CR16","doi-asserted-by":"crossref","unstructured":"Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, et al. Targeting tumor vasculature with an oncolytic virus. Mol Ther. 2011;19:886\u201394.","DOI":"10.1038\/mt.2011.26"},{"key":"744_CR17","doi-asserted-by":"crossref","unstructured":"DeRose YS, Wang G, Lin Y-C, Bernard PS, Buys SS, Ebbert MTW, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17:1514\u201320.","DOI":"10.1038\/nm.2454"},{"key":"744_CR18","doi-asserted-by":"crossref","unstructured":"Falls T, Roy DG, Bell JC, Bourgeois-Daigneault MC. Murine tumor models for oncolytic rhabdo-virotherapy. ILAR J. 2016;57(1):73\u201385.","DOI":"10.1093\/ilar\/ilv048"},{"key":"744_CR19","doi-asserted-by":"crossref","unstructured":"Diallo J-S, Roy D, Abdelbary H, De Silva N, Bell JC. Ex vivo infection of live tissue with oncolytic viruses. J Vis Exp. 2011;e2854.","DOI":"10.3791\/2854"},{"key":"744_CR20","doi-asserted-by":"crossref","unstructured":"Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C, et al. Poxviruses and immune evasion. Annu Rev Immunol. 2003;21:377\u2013423.","DOI":"10.1146\/annurev.immunol.21.120601.141049"},{"key":"744_CR21","doi-asserted-by":"crossref","unstructured":"Le Boeuf F, Batenchuk C, V\u00e4h\u00e4-Koskela M, Breton S, Roy D, Lemay C, et al. Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat Commun. 2013;4:1974.","DOI":"10.1038\/ncomms2974"},{"key":"744_CR22","doi-asserted-by":"crossref","unstructured":"Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol. 2002;76:895\u2013904.","DOI":"10.1128\/JVI.76.2.895-904.2002"},{"key":"744_CR23","doi-asserted-by":"crossref","unstructured":"Bourgeois-Daigneault M-C, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, et al. Oncolytic vesicular stomatitis virus expressing interferon-\u03b3 has enhanced therapeutic activity. Mol Ther\u2013Oncolytics. 2016;3:16001.","DOI":"10.1038\/mto.2016.1"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-016-0744-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0744-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-016-0744-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T04:32:23Z","timestamp":1568262743000},"score":1,"resource":{"primary":{"URL":"http:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-016-0744-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1186\/s13058-016-0744-y","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]},"article-number":"83"}}